We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




HDL Primarily Produced in the Liver

By Biotechdaily staff writers
Posted on 17 May 2005
Researchers have used a mouse model to show that although the gene that controls production of HDLs (high density lipoproteins), the transporter of "good cholesterol,” is found in many different tissues, most HDLs are actually produced in the liver.

Investigators at Wake Forest University Baptist Medical Center (Winston-Salem, NC, USA) genetically engineered a line of mice lacking the gene ABCA1 in their livers. More...
The protein produced by ABCA1 controls the rate-limiting step in HDL particle assembly by mediating efflux of cholesterol and phospholipids from cells to lipid-free apoA-I, which forms nascent HDL particles.

Results published in the May 2005 issue of the Journal of Clinical Investigation revealed that HDL levels in the blood of the modified animals were reduced by nearly 80% from those seen in control mice. Circulating HDL was broken down in the kidneys of the engineered mice at a rate twice that of normal animals, while there was no difference in the rate of HDL catabolism in their livers. The lipid profiles of the engineered mice closely resembled those seen in the rare human syndrome Tangier disease.

"In studies of mice, we provided the first definitive proof that the liver is the source of about 80% of the high-density lipoprotein, or "good” cholesterol, that circulates in the blood,” said senior author Dr. John S. Parks, professor of pathology at Wake Forest University Baptist Medical Center. "These results profoundly alter our concept of how HDL is manufactured in the body and establish the liver as the single most important source of HDL in a mouse model. Understanding more about how HDL is produced could lead to new treatments to raise its levels.”

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.